Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | UTS2R | Q9UKP6 | 4/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.35 |
| ▸ | ACHE | P22303 | 1/20 | 0.35 |
| ▸ | BACE1 | P56817 | 1/20 | 0.35 |
| ▸ | CCR5 | P51681 | 2/20 | 0.34 |
| ▸ | JAK2 | O60674 | 1/20 | 0.34 |
| ▸ | ROCK2 | O75116 | 4/20 | 0.34 |
| ▸ | ROCK1 | Q13464 | 4/20 | 0.34 |
| ▸ | NAMPT | P43490 | 1/20 | 0.33 |
| ▸ | ELANE | P08246 | 1/20 | 0.32 |
| ▸ | HTR2A | P28223 | 1/20 | 0.32 |
| ▸ | HTR2C | P28335 | 1/20 | 0.32 |
| ▸ | CCR2 | P41597 | 2/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1497057 | 0.95 | ACHE (0.38) | UTS2RMAPK1ACHEBACE1JAK2 | |
| SCHEMBL1497013 | 0.95 | CSF1R (0.36) | MAPK1CCR5ELANECCR2 | |
| SCHEMBL1496855 | 0.93 | CD274 (0.40) | JAK2ROCK2ROCK1HTR2AHTR2C | |
| SCHEMBL1496991 | 0.91 | CSF1R (0.35) | ACHEBACE1ELANE | |
| SCHEMBL1496958 | 0.89 | CD274 (0.39) | JAK2HTR2AHTR2C | |
| SCHEMBL10476436 | 0.86 | UTS2R (0.44) | UTS2RROCK2ROCK1 | |
| SCHEMBL1496935 | 0.86 | UTS2R (0.38) | UTS2RMAPK1CCR5ROCK2ROCK1 | |
| SCHEMBL3230179 | 0.85 | JAK2 (0.38) | JAK2 | |
| SCHEMBL1496836 | 0.84 | UTS2R (0.39) | UTS2RROCK2ROCK1ELANE | |
| SCHEMBL3230156 | 0.84 | JAK2 (0.38) | JAK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120202808-A1 | NOVEL THIOPHENEDIAMINE DERIVATIVE HAVING UREA STRUCTURE | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2012-08-09 | — | — | US | disclosed |
| EP-2292611-B1 | NOVEL THIOPHENEDIAMINE DERIVATIVE HAVING UREA STRUCTURE | SANTEN PHARMACEUTICAL CO LTD (JP) | 2012-07-25 | — | — | EP | disclosed |
| EP-2292611-A1 | NOVEL THIOPHENEDIAMINE DERIVATIVE HAVING UREA STRUCTURE | Santen Pharmaceutical Co., Ltd (JP) | 2011-03-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120202808-A1 | NOVEL THIOPHENEDIAMINE DERIVATIVE HAVING UREA STRUCTURE | CBR1, NAT1, PRMT1 | UTS2R 195/4885MAPK1 1105/4885ACHE 1166/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.